• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales

    11/6/23 8:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $BIAF alert in real time by email

    bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced the appointment of Dallas J. Coleman as National Director of Sales. Mr. Coleman has more than 15 years of experience in medical sales and marketing, most recently as Executive Account Manager for the respiratory portfolio of Olympus America's therapeutic solutions division.

    Reporting to bioAffinity Technologies President and Chief Executive Officer Maria Zannes, Mr. Coleman is responsible for leading the CyPath® Lung sales team and sourcing new business opportunities.

    "We are delighted to welcome Dallas to our management team in this newly created position. His experience and demonstrated track record in building strong relationships with our target customers and creating effective sales organizations is a timely and strategic fit as we ramp up the commercialization of CyPath® Lung, our noninvasive test for the detection of early-stage lung cancer," Ms. Zannes said. "As a near-term priority, his expertise in developing commercial initiatives is expected to help drive the expansion of our pilot market launch across Texas and pave the way for the national rollout of CyPath® Lung."

    At Olympus America, Mr. Coleman was part of a team that launched new products, including spiration valves for COPD and emphysema patients, navigational bronchoscopy to access peripheral nodules, and ultrasound bronchoscopes used to sample lymph nodes for cancer staging, primarily marketing to pulmonologists, interventional pulmonologists, thoracic surgeons and physicians treating patients with lung disease. Prior to that, he held sales management positions at Caldera Medical, a medical device company focused on women's health, and Ecolab, a global sustainability leader providing water, hygiene and hospital infection prevention solutions and services.

    "My career has consistently revolved around extending the lives of patients and improving their quality of life. For the past five years, I have provided physicians and hospitals with innovative devices for the diagnosis and treatment of pulmonary diseases, including lung cancer," Mr. Coleman said. "More than 14 million Americans are at high risk for lung cancer, and the opportunity to share CyPath® Lung with their care teams is highly motivating. I look forward to working with my new colleagues at bioAffinity to accelerate the rollout of this innovative product and help physicians treat lung cancer in its early stages, with better outcomes for patients."

    About CyPath® Lung

    CyPath® Lung uses flow cytometry to identify cell populations in patient sputum that indicate malignancy. Automated data analysis developed using proprietary artificial intelligence can help determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin, TCPP, that is preferentially taken up by cancer and cancer-related cells. In a clinical trial, CyPath® Lung showed 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Half of all patients in the trial who had cancer were diagnosed in early Stages I or II. Diagnosing and treating early-stage cancer can increase patient survival and improve outcomes.

    About bioAffinity Technologies, Inc.

    bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. Research and optimization of the Company's platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio. For more information, visit www.bioaffinitytech.com and follow us on LinkedIn, Facebook and Twitter.

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding Mr. Coleman's expected contributions, including his expertise in developing commercial initiatives to drive the expansion of the Company's pilot market launch across Texas, paving the way for the national rollout of CyPath® Lung, bringing CyPath® Lung to market, and helping physicians treat lung cancer in its early stages with better outcomes for patients. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to successfully integrate Mr. Coleman with the management team and derive the contributions expected from him and the other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231106271829/en/

    Get the next $BIAF alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BIAF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIAF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools

      bioAffinity Technologies' noninvasive sputum test flagged difficult-to-diagnose cancer at earliest Stage 1A bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company addressing the need for noninvasive, accurate tests for the detection of early-stage cancer, today released a compelling new case study in which CyPath® Lung identified a Stage 1A neuroendocrine tumor in the patient's lung after PET scan, bronchoscopies and a serum tumor marker test suggested it was non-cancerous inflammation. "We believe that this patient's experience demonstrates the high added value that CyPath® Lung brings to the diagnostic pathway. Multiple procedures and diagnostic tools were incon

      7/23/25 8:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

      New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung. "As with the recent announcement of the award of our patent in China, this Canadian

      7/22/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

      One third of world's smokers live in China, which has highest rate of lung cancer bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry. China represents a large prospective market for CyPath® Lung with more than 300 million people who smoke, or a third of the world's total smokers, according to th

      7/15/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    SEC Filings

    See more
    • bioAffinity Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

      7/25/25 4:15:56 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

      7/23/25 4:30:48 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)

      7/22/25 4:30:55 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Leadership Updates

    Live Leadership Updates

    See more
    • bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health. As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board

      6/11/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

      bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine, clinical research, medical innovation, and interventional pulmonology to the role. Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved resea

      5/20/25 9:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

      Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)) ("bioAffinity" or the "Company"), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 as Senior Vice President of Research and Development, Dr. Bauta was the Associate Director of Science at Genzyme Corporation and held a similar positi

      11/4/24 8:00:00 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by bioAffinity Technologies Inc.

      SC 13G - bioAffinity Technologies, Inc. (0001712762) (Subject)

      10/10/23 6:03:06 AM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Reveles Xavier Trinidad was granted 21,604 shares, increasing direct ownership by 106% to 41,943 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:26 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Secretary, EVP, Gen. Counsel Zannes Timothy P was granted 8,641 shares, increasing direct ownership by 19% to 54,765 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:20 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • President & CEO Zannes Maria was granted 37,037 shares, increasing direct ownership by 15% to 280,359 units (SEC Form 4)

      4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)

      1/14/25 4:15:23 PM ET
      $BIAF
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $BIAF
    Financials

    Live finance-specific insights

    See more
    • Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c

      1/10/25 9:00:00 AM ET
      $BIAF
      $ENLV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (NASDAQ:BTCY) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Biotricity: https://www.redchip.com/assets/access/btcy_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of car

      7/12/24 9:35:00 AM ET
      $BIAF
      $BTCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
    • BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs target

      7/5/24 9:00:00 AM ET
      $BIAF
      $BIVI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations